TITLE

COX-2 EXPRESSION IS AN INDICATOR OF POOR SURVIVAL IN PATIENTS UNDERGOING RESECTION FOR OESOPHAGEAL ADENOCARCINOMA

AUTHOR(S)
Bhandon, P.; Stacey, B.; Bateman, A.C.; Patel, P.
PUB. DATE
April 2003
SOURCE
Gut;Apr2003 Supplement 1, Vol. 52, pA47
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: The clinical relevance of cox-2 overexpression in oesophageal adenocarcinoma is uncertain. Aim: To test the hypothesis that cox-2 overexpression in oesophageal adenocarcinoma is associated with decreased patient survival. Methods: Oesophageal resection specimens were obtained from a retrospective sample of patients who underwent intentionally curative resection for oesophageal adenocarcinoma (1990-96). Paraffin sections were used for immunohistochemical staining with a monoclonal antibody for cox-2 (Caymen chemicals) at a dilution of 1/100. Cox-2 expression was assessed using a semi-quantitative intensity-proportion scoring system (H-score i.e. intensity (0-3) × proportion of positive ceils (%); possible scores from 0-300). Statistical analysis was performed using the Mann-Whitney U test and regression analysis. Results: Specimens were identified from 79 patients with full pathological and clinical follow up data (minimum five years). There was a negative association between cox-2 expression and survival (p=0.03). Conclusion: Cox-2 overexpression is a marker of poor survival in patients with oesophageal adenocarcinoma. Differences in survival between groups with high and Iow cox-2 expression were not accounted for by variations in tumour differentiation or nodal stage.
ACCESSION #
9747584

 

Related Articles

  • Prognostic significance of cyclooxygenase-2 (COX-2) expression patients with surgically resectable adenocarcinoma of oesophagus. Bhandari, Pradeep; Bateman, Adrian C; Mehta, Raj L; Stacey, Bernard SF; Johnson, Penny; Cree, Ian A; Nicolantonio, Federica Di; Patel, Praful // BMC Cancer;2006, Vol. 6, p134 

    Background: COX-2 expression in tumour cells has been associated with poor prognosis in gastrointestinal and non-gastrointestinal cancers. The aim of our study was to test the hypothesis that higher levels of COX-2 expression are prognostically related to poor clinico-pathologic features in...

  • Testing for Colon Neoplasia Susceptibility Variants at the Human COX2 Locus. Wiesner, Georgia L.; Platzer, Petra; Buxbaum, Sarah; Lewis, Susan; MacMillen, Mellissa; Olechnowicz, Joseph; Willis, Joseph; Chakravarti, Aravinda; Elston, Robert C.; Markowitz, Sanford D. // JNCI: Journal of the National Cancer Institute;04/18/2001, Vol. 93 Issue 8, p635 

    Examines whether the human cyclooxygenase 2 (COX2) locus may be linked to colon neoplasia in humans. Use of affected sibling-pair method to test for linkage of the human COX2 locus to colon neoplasia; Evaluation of COX2 susceptibility alleles in subpopulations of sibships with colon neoplasia.

  • VARIABLE CYCLOOXYGENASE (COX)-2 EXPRESSION IN BARRETT'S ASSOCIATED ADENOCARCINOMA: RELATIONSHIP TO TUMOUR DIFFERENTIATION. Abdalla, S.; Sanderson, I. R.; Novelli, M. R.; Lovat, L. B.; Fitzgerald, R. C. // Gut;Apr2004 Supplement 3, Vol. 53, pA58 

    Population based studies, animal models, and cell line experiments suggest a strong association between cyclooxygenase (COX)-2 and human cancer. Barrett's oesophageal epithelium (BE) expresses more COX-2 compared with normal squamous epithelium (NE). However, there are conflicting data regarding...

  • Sulindac Prevents Esophageal Adenocarcinomas Induced by Gastroduodenal Reflux in Rats. Sung Wook Kim; Tae Jung Jang; Ki Hoon Jung; Jung Il Suh // Yonsei Medical Journal;12/31/2008, Vol. 48 Issue 6, p1020 

    Purpose: It is known that cyclooxygenase (COX)-2 expression is increased in Barrett's esophagus and esophageal adenocarcinomas. We studied COX-2 expression and the effect sulindac has on the genesis of Barrett's esophagus and adenocarcinoma in rats undergoing esophagogastroduodenal anastomosis...

  • SUPPRESSION OF COX-2 EXPRESSION IN HUMAN ADENOCARCINOMA CELLS (OE33) CULTURED WITH EICOSAPENTAENOIC ACID (EPA). Lee, G.; Lund, E. K.; Rhodes, M.; Johnson, I. T. // Gut;Apr2004 Supplement 3, Vol. 53, pA26 

    Oesophageal adenocarcinoma initiation and progression is associated with elevated levels of cyclo-oygenase 2 (COX-2) expression. The use of synthetic COX-2 inhibitors as chemo-preventative therapy is limited by side effects. There is epidemiological and experimental evidence to suggest that...

  • Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma. Yong Cui; Chang Dong; Bing-Qun Wu; Xin-Chun Duan; Guan Shi; Min Gong; Tian-You Wang // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC44 

    Background: Esophageal squamous cell carcinoma (ESCC) is a frequently occurring cancer with poor prognosis despite combined therapeutic strategies. The aim of the current study was to elucidate a further finding on the clinicopathologic significance of immunohistochemical expression of...

  • THE ACCURACY OF EUS, HCT AND PET IN RE-STAGING OF OESOPHAGEAL CANCER FOLLOWING CHEMOTHERAPY. Meenan, J.; Rankin, S.; Marx, G.; Harper, P. // Gut;Apr2003 Supplement 1, Vol. 52, pA31 

    The best approach to re-staging oesophageal cancer following chemotherapy is unknown. Potential limitations exist for all imaging modalities: hCT and EUS cannot differentiate between viable tumour and inflammation, whereas although PET scanning may detect remnant malignancy, it lacks spatial...

  • Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma. Nakajima, M; Fukuchi, M; Miyazaki, T; Masuda, N; Kato, H; Kuwano, H // British Journal of Cancer;6/2/2003, Vol. 88 Issue 11, p1734 

    Axin is a negative regulator of the Wnt signalling pathway, and genetic alterations of AXIN1 have been suggested to be an important factor of carcinogenesis in some tumours. The objective of this study was to clarify the clinicopathologic and prognostic significance of Axin in oesophageal...

  • Chemoprevention and Barrett's Esophagus: Decisions, Decisions. Falk, Gary W.; Jankowski, Janusz // American Journal of Gastroenterology;Oct2008, Vol. 103 Issue 10, p2443 

    The incidence of esophageal adenocarcinoma continues to increase at a rate greater than that of any other cancer in the western world. Current strategies to deal with this situation are problematic, and the time has come for new approaches to this problem. Chemoprevention is one such approach....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics